基于生物标志物预测急性冠脉综合征患者复发性缺血事件
本研究利用 PLATO 试验 10,713 例患者开发基于生物标志物的预测模型,并在 TRACER 试验 3,508 例患者中外部验证,构建了包含年龄、生物标志物(GDF-15 和 NT-proBNP)及临床变量的 8 项 ABC-ACS 缺血评分。该评分对 1 年心血管死亡/心肌梗死风险校准良好,开发队列和验证队列 C 指数分别为 0.71 和 0.72,对心血管死亡预测更优(C 指数 0.80 和 0.84)。
要点
- ABC-ACS 缺血评分包含年龄、GDF-15、NT-proBNP、冠脉病变范围等 8 项预测因子。
- 评分对 1 年心血管死亡/心梗风险区分度良好,C 指数 0.71–0.72。
- 评分对心血管死亡预测性能更佳,C 指数达 0.80–0.84。
核心结论
- 开发并验证了用于接受经皮冠状动脉介入治疗的 ACS 患者 1 年心血管死亡/心梗风险的 8 项 ABC-ACS 缺血评分。
- 该评分校准良好且区分度佳,可能有助于 ACS 患者的风险预测和决策支持。
研究设计与样本
- 基于 PLATO 试验 10,713 例患者作为开发队列,TRACER 试验 3,508 例患者作为外部验证队列。
- 使用 Cox 回归模型评估与心血管死亡/心梗风险相关的变量,并基于近似全模型的变量子集推导评分。
主要发现
- 开发队列和验证队列分别发生 632 次和 190 次心血管死亡/心梗事件。
- 生长分化因子 15 和 N 末端 B 型利钠肽原是最重要的预测因子,预后价值优于所有候选变量。
- 最终模型包含 8 项:年龄、生物标志物(GDF-15 和 NT-proBNP)、临床变量(冠脉病变范围、既往血管疾病、Killip 分级、ACS 类型、P2Y12 抑制剂)。
- 模型对 1 年心血管死亡/心梗风险的 C 指数在开发队列和验证队列分别为 0.71 和 0.72;对心血管死亡的 C 指数分别为 0.80 和 0.84。
临床怎么用
- 该评分可用于接受经皮冠状动脉介入治疗的 ACS 患者 1 年心血管死亡/心梗风险预测和决策支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with acute coronary syndrome (ACS), there is residual and variable risk of recurrent ischemic events. OBJECTIVES: This study aimed to develop biomarker-based prediction models for 1-year risk of cardiovascular (CV) death and myocardial infarction (MI) in patients with ACS undergoing percutaneous coronary intervention. METHODS: We included 10,713 patients from the PLATO (A Comparison of Ticagrelor [AZD6140] and Clopidogrel in Patients With Acute Coronary Syndrome) trial in the development cohort and externally validated in 3,508 patients from the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial. Variables contributing to risk of CV death/MI were assessed using Cox regression models, and a score was derived using subsets of variables approximating the full model. RESULTS: There were 632 and 190 episodes of CV death/MI in the development and validation cohorts. The most important predictors of CV death/MI were the biomarkers, growth differentiation factor 15, and N-terminal pro-B-type natriuretic peptide, which had greater prognostic value than all candidate variables. The final model included 8 items: age (A), biomarkers (B) (growth differentiation factor 15 and N-terminal pro-B-type natriuretic peptide), and clinical variables (C) (extent of coronary artery disease, previous vascular disease, Killip class, ACS type, P2Y12 inhibitor). The model, named ABC-ACS ischemia, was well calibrated and showed good discriminatory ability for 1-year risk of CV death/MI with C-indices of 0.71 and 0.72 in the development and validation cohorts, respectively. For CV death, the score performed better, with C-indices of 0.80 and 0.84 in the development and validation cohorts, respectively. CONCLUSIONS: An 8-item score for the prediction of CV death/MI was developed and validated for patients with ACS undergoing percutaneous coronary intervention. The ABC-ACS ischemia score showed good calibration and discrimination and might be useful for risk prediction and decision support in patients with ACS. (A Comparison of Ticagrelor [AZD6140] and Clopidogrel in Patients With Acute Coronary Syndrome [PLATO]; NCT00391872; Trial to Assess the Effects of Vorapaxar [SCH 530348; MK-5348] in Preventing Heart Attack and Stroke in Participants With Acute Coronary Syndrome [TRACER]; NCT00527943).
引用
- Batra, Lindbäck, Becker, et al. Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2022. PMID: 36302586. doi:10.1016/j.jacc.2022.08.767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。